Photo from wikipedia
HSV‐2 infected more than 491 million people aged 15–49 world‐wide in 2016. The morbidity associated with recurrent infections and the increased risk of HIV infection make this a major health… Click to show full abstract
HSV‐2 infected more than 491 million people aged 15–49 world‐wide in 2016. The morbidity associated with recurrent infections and the increased risk of HIV infection make this a major health problem. To date there is no effective vaccine. Because HSV‐2 ascends to the dorsal route ganglion within 12–18 h of infection, an effective vaccine will need to elicit a strong local resident CD8+ T cell response to prevent the infection from becoming life‐long.
Keywords:
primary oral;
followed vaginal;
infection;
oral vaccination;
vaccination followed;
vaginal pull
Journal Title: American Journal of Reproductive Immunology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: American Journal of Reproductive Immunology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!